TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36749850

Group type: EXPERIMENTAL
Intervention: Transitional Care Model Stroke Turkey program (13 to 20 weeks duration, including 12-week follow-up, minimum of three hospital visits, one home visit, minimum 18 phone calls, and web-based training)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 126
Study: 36749851

Group type: EXPERIMENTAL
Intervention: Community-level empowerment intervention (multiservice drop-in SPARC center)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Control (areas not served by SPARC)
Number of subjects: 385
Study: 36749873

Group type: EXPERIMENTAL
Intervention: LOS+FFX+CRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: FFX+CRT
Number of subjects: 0
Study: 36749915

Group type: EXPERIMENTAL
Intervention: Ultrasound treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 42
Study: 36750134

Group type: EXPERIMENTAL
Intervention: THC (8 mg THC for 75 kg person)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: THC + CBD (8 mg THC and 24 mg CBD for 75 kg person)
Number of subjects: 48

Group type: COMPARATOR
Intervention: PLA (matched placebo)
Number of subjects: 48
Study: 36750244

Group type: EXPERIMENTAL
Intervention: Baseline liver stiffness (LS) ≥16.6 kPa for predicting progression to cirrhosis
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Increase in liver stiffness (LS) of ≥5 kPa (and ≥20%)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Baseline liver stiffness (LS) ≥30.7 kPa for predicting liver-related events
Number of subjects: 734
Study: 36750275

Group type: EXPERIMENTAL
Intervention: Balloon-expandable TAVI (Edwards SAPIEN 3/3 Ultra)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Pre-existing right bundle branch block
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Valve oversizing (higher than manufacturer-recommended sizing, mean area oversizing, use of 29 mm valve)
Number of subjects: 300

Group type: COMPARATOR
Intervention: SAPIEN 3 vs SAPIEN 3 Ultra
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Implantation depth and postdelivery balloon dilatation
Number of subjects: 300
Study: 36750353

Group type: EXPERIMENTAL
Intervention: Leaflet resection
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Leaflet preservation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Annuloplasty size <34 mm
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Annuloplasty size ≥34 mm
Number of subjects: 104

Group type: COMPARATOR
Intervention: Intraoperative TEE MV gradients
Number of subjects: 104
Study: 36750531

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ravulizumab
Number of subjects: 34

Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 34
Study: 36750617

Group type: EXPERIMENTAL
Intervention: IRS-High group
Number of subjects: 648

Group type: COMPARATOR
Intervention: Pembrolizumab monotherapy
Number of subjects: 648

Group type: COMPARATOR
Intervention: First-line pembrolizumab monotherapy
Number of subjects: 648

Group type: COMPARATOR
Intervention: IRS-High/TMB-Low
Number of subjects: 648
Study: 36750768

Group type: EXPERIMENTAL
Intervention: Chronic pain observed in patients with gunshot wounds
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Wounds in 1 or 2 anatomical parts of the body
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Wounds in 3 or more anatomical parts of the body
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Neuropathic pain component detected using DN4
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Acute stress reaction diagnosed using HADS
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Satisfaction with treatment results measured by CQLS
Number of subjects: 769

Group type: COMPARATOR
Intervention: Comparison of chronic pain risk
Number of subjects: 769
Study: 36750848

Group type: EXPERIMENTAL
Intervention: Arm-B (linac-based SRS)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Arm-A (multi-source gamma-ray system)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Both Arms (Arm-A and Arm-B)
Number of subjects: 251
Study: 36750858

Group type: EXPERIMENTAL
Intervention: Postoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy (5 cycles of weekly TC: paclitaxel 50 mg/m2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Postoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy
Number of subjects: 70
Study: 36750867

Group type: EXPERIMENTAL
Intervention: Tele-Harm Reduction
Number of subjects: 240

Group type: COMPARATOR
Intervention: Off-site linkage to HIV care
Number of subjects: 240
Study: 36750879

Group type: EXPERIMENTAL
Intervention: Digital Buddy intervention (intergenerational mentoring with a young volunteer), 23 hours of training over 6 months, 14 sessions.
Number of subjects: 292

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 292
Study: 36750897

Group type: EXPERIMENTAL
Intervention: Health education intervention provided to health care professionals (3 sessions using Power Point presentations, posters, pamphlets, and videos)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 0
Study: 36750902

Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccines
Number of subjects: 89
Study: 36750904

Group type: EXPERIMENTAL
Intervention: Beetroot juice (800 mg acutely and 400 mg daily for a week)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 36750930

Group type: EXPERIMENTAL
Intervention: Knee injury and OA Outcome Score-12 (KOOS-12)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified OA Cost and Consequences Questionnaire (OCC-Q)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Work Productivity and Activity Impairment Questionnaire (WPAI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life, physical performance, global assessment, satisfaction, and physical activity levels
Number of subjects: 0
Study: 36750953

Group type: EXPERIMENTAL
Intervention: Tight control (subgroup 2 weights)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Less-tight control (subgroup 3 weights)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Equal weights
Number of subjects: 183

Group type: COMPARATOR
Intervention: Subgroup (1) weights (equal prioritizers)
Number of subjects: 183
Study: 36751345

Group type: EXPERIMENTAL
Intervention: CIRCA study intervention (observational cohort study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires at 90 days, 180 days, and 12 months for surviving patients and family members
Number of subjects: 0
Study: 36751400

Group type: EXPERIMENTAL
Intervention: Improved lifestyle (measured by lifestyle change scores)
Number of subjects: 613
Study: 36751643

Group type: EXPERIMENTAL
Intervention: Health-related quality of life measured by short form 12 mental component score (MCS)
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: Health-related quality of life measured by short form 12 physical health component score (PCS)
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: COVID-19 infection rates
Number of subjects: 1605
Study: 36751950

Group type: EXPERIMENTAL
Intervention: Bimekizumab after switching from adalimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimekizumab after switching from ustekinumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimekizumab after switching from secukinumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 0
Study: 36752055

Group type: EXPERIMENTAL
Intervention: Rapid molecular drug susceptibility assays for linezolid, bedaquiline, clofazimine, nitroimidazoles (pretomanid and delamanid), and pyrazinamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Next generation molecular assays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequencing assays for novel and repurposed drug compounds
Number of subjects: 0
Study: 36752104

Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS) measures
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire-12 item
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Clinician ratings
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Performance tests
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Clinical adverse events
Number of subjects: 648
Study: 36752227

Group type: EXPERIMENTAL
Intervention: TMVr with MitraClip implant plus guideline-directed medical therapy (GDMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 0
Study: 36752231

Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair with the MitraClip device
Number of subjects: 500

Group type: COMPARATOR
Intervention: Surgical mitral valve repair
Number of subjects: 500
Study: 36752290

Group type: EXPERIMENTAL
Intervention: SIMDA Computerized Medical Decision Support System (CMDSS)
Number of subjects: 2834
Study: 36752460

Group type: EXPERIMENTAL
Intervention: Apnea group (n = 64)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (n = 64)
Number of subjects: 128
Study: 36752462

Group type: EXPERIMENTAL
Intervention: Homogenous simplified catheter ablation strategy
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Complete LP abolition
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Composite endpoint of LP abolition and noninducibility
Number of subjects: 309
Study: 36752464

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) analysis in WBS subjects
Number of subjects: 18
Study: 36752466

Group type: EXPERIMENTAL
Intervention: Ultra-low temperature cryoablation (ULTC) using near-critical nitrogen (-196ºC)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ultra-low temperature cryoablation (ULTC)
Number of subjects: 13
Study: 36752467

Group type: EXPERIMENTAL
Intervention: 90-W ablation (90 W over 4 seconds)
Number of subjects: 180

Group type: COMPARATOR
Intervention: 35/50-W ablation (titrated up to ablation index >550 anteriorly and >400 posteriorly)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 180
Study: 36752484

Group type: EXPERIMENTAL
Intervention: QDM catheter with vHPSD mode (90 W, ≤4 seconds)
Number of subjects: 166
Study: 36752714

Group type: EXPERIMENTAL
Intervention: Mindfulness-based music therapy intervention
Number of subjects: 0
Study: 36752726

Group type: EXPERIMENTAL
Intervention: Belzutifan plus lenvatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cabozantinib
Number of subjects: 0
Study: 36752782

Group type: EXPERIMENTAL
Intervention: Remote patient management (RPM) plus usual care (UC) (n = 796)
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Usual care (UC) only (n = 775)
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: RPM group (n = 667)
Number of subjects: 1538

Group type: COMPARATOR
Intervention: RPM group vs UC group
Number of subjects: 1538
Study: 36752895

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ), n=30
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo, n=30
Number of subjects: 60
Study: 36752899

Group type: EXPERIMENTAL
Intervention: Rb-PET-MPI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tc-SPECT-MPI
Number of subjects: 0
Study: 36753043

Group type: EXPERIMENTAL
Intervention: Girl2Girl text messaging-based pregnancy prevention program
Number of subjects: 948

Group type: COMPARATOR
Intervention: Attention-matched control program discussing healthy lifestyle topics
Number of subjects: 948
Study: 36753063

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Moderate-intensity steady-state (MISS) exercise training
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 382
Study: 36753281

Group type: EXPERIMENTAL
Intervention: Gefitinib plus chemotherapy (pemetrexed with platinum)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Gefitinib alone
Number of subjects: 161
Study: 36753315

Group type: EXPERIMENTAL
Intervention: Foster families
Number of subjects: 250
Study: 36753410

Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) with patient education
Number of subjects: 49

Group type: COMPARATOR
Intervention: Clinical decision support (CDS) without patient education
Number of subjects: 49
Study: 36753453

Group type: EXPERIMENTAL
Intervention: Short-term pain recall
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Long-term pain recall
Number of subjects: 59

Group type: COMPARATOR
Intervention: Mechanical pain
Number of subjects: 59
Study: 36753564

Group type: EXPERIMENTAL
Intervention: D2C7-immunotoxin (IT) + αCD40 costimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: D2C7-immunotoxin (IT)
Number of subjects: 0
Study: 36753688

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 30
Study: 36753698

Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg twice a day
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo twice a day
Number of subjects: 92
Study: 36753722

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (265 sessions; 25-40 min)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pre-exercise blood glucose
Number of subjects: 28
Study: 36753834

Group type: EXPERIMENTAL
Intervention: Apatinib 250 mg once daily and camrelizumab 200 mg once every two weeks intravenously every 28-day cycle
Number of subjects: 30
Study: 36753836

Group type: EXPERIMENTAL
Intervention: Avelumab alone (Arm A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avelumab with cetuximab (Arm B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avelumab alone (Arm A) or with cetuximab (Arm B)
Number of subjects: 0
Study: 36754009

Group type: EXPERIMENTAL
Intervention: Tolvaptan and Octreotide-LAR (two 20-mg i.m. injections)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Tolvaptan and Placebo (two i.m. 0.9% saline solution injections)
Number of subjects: 19
Study: 36754065

Group type: EXPERIMENTAL
Intervention: CDSS-assisted endoscopy
Number of subjects: 2524

Group type: COMPARATOR
Intervention: Conventional screening endoscopy
Number of subjects: 2524
Study: 36754096

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 93

Group type: COMPARATOR
Intervention: Tai Chi
Number of subjects: 93

Group type: COMPARATOR
Intervention: Gut Microflora
Number of subjects: 93
Study: 36754106

Group type: EXPERIMENTAL
Intervention: Immediate revascularization
Number of subjects: 248

Group type: COMPARATOR
Intervention: Staged revascularization
Number of subjects: 248
Study: 36754158

Group type: EXPERIMENTAL
Intervention: Myo-inositol, probiotics, and micronutrient supplement (vitamins B2, B6, B12, D, zinc)
Number of subjects: 1437

Group type: COMPARATOR
Intervention: Standard supplement (folic acid, iron, calcium, iodine, β-carotene)
Number of subjects: 1437
Study: 36754174

Group type: EXPERIMENTAL
Intervention: 0.5 mg OPT-302 + 0.5 mg ranibizumab
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: 2.0 mg OPT-302 + 0.5 mg ranibizumab
Number of subjects: 366

Group type: COMPARATOR
Intervention: Sham + 0.5 mg ranibizumab
Number of subjects: 366
Study: 36754250

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 2007

Group type: COMPARATOR
Intervention: Control (usual obesity care)
Number of subjects: 2007
Study: 36754451

Group type: EXPERIMENTAL
Intervention: PexaVec/durvalumab/tremelimumab
Number of subjects: 34

Group type: COMPARATOR
Intervention: PexaVec/durvalumab
Number of subjects: 34
Study: 36754548

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg
Number of subjects: 6991

Group type: COMPARATOR
Intervention: adalimumab and methotrexate
Number of subjects: 6991
Study: 36754691

Group type: EXPERIMENTAL
Intervention: ViV-TAVI with high-risk anatomy (VIVID type IIB, IIIB, or IIIC)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Coronary protection using wire protection or BASILICA
Number of subjects: 137

Group type: COMPARATOR
Intervention: Patients with high-risk anatomy without coronary protection
Number of subjects: 137
Study: 36754697

Group type: EXPERIMENTAL
Intervention: Arterial Doppler during active CPR
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Arterial Doppler during pauses in CPR
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Arterial Doppler detecting organized cardiac activity
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Patients with visible native cardiac pulsations during active CPR
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Arterial Doppler with organized contractions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Arterial Doppler with disorganized contractions
Number of subjects: 16
Study: 36754922

Group type: EXPERIMENTAL
Intervention: Video gaming (Temple Run and Piano Tiles 2)
Number of subjects: 0
Study: 36754937

Group type: EXPERIMENTAL
Intervention: Moderate-intensity yoga intervention (3×/week, 50 min for 8 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Waitlist control arm
Number of subjects: 86
Study: 36755110

Group type: EXPERIMENTAL
Intervention: Pre-hospital rule-out with POC troponin measurement
Number of subjects: 863

Group type: COMPARATOR
Intervention: Direct transfer to the ED
Number of subjects: 863
Study: 36755187

Group type: EXPERIMENTAL
Intervention: School-based health center model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 36755231

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36755279

Group type: EXPERIMENTAL
Intervention: Preconception micronutrient supplementation
Number of subjects: 1599
Study: 36755288

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological inhibition of antioxidant responses
Number of subjects: 0
Study: 36755328

Group type: EXPERIMENTAL
Intervention: Continue standard TNFi dosing
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Fixed longer dosing intervals of TNFi
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Stop TNFi
Number of subjects: 198
Study: 36755418

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional (noncellular) therapies
Number of subjects: 0
Study: 36756354

Group type: EXPERIMENTAL
Intervention: BDD-NET
Number of subjects: 0

Group type: COMPARATOR
Intervention: Online supportive psychotherapy
Number of subjects: 0
Study: 36756676

Group type: EXPERIMENTAL
Intervention: Enavogliflozin 0.3 mg/day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 200
Study: 36756808

Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal inactivated influenza vaccine
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Arsenic exposure
Number of subjects: 784
Study: 36756843

Group type: EXPERIMENTAL
Intervention: Digital peer support intervention via the Acceset platform
Number of subjects: 100
Study: 36756874

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 786

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 786
Study: 36756899

Group type: EXPERIMENTAL
Intervention: rFVIIa (recombinant activated factor VIIa; 80 μg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 36756959

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 905
Study: 36757197

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus carboplatin (nab-P/C)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: carboplatin
Number of subjects: 408
Study: 36757300

Group type: EXPERIMENTAL
Intervention: Tele-assessment methods for rehabilitation needs
Number of subjects: 0
Study: 36757318

Group type: EXPERIMENTAL
Intervention: Azithromycin (2-g oral dose)
Number of subjects: 29278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29278
Study: 36757390

Group type: EXPERIMENTAL
Intervention: Dasatinib (50 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Dasatinib generic (50 mg)
Number of subjects: 56
Study: 36757424

Group type: EXPERIMENTAL
Intervention: Robotic stereotactic body radiotherapy (SBRT) with 35 Gy in 5 fractions
Number of subjects: 85
Study: 36757445

Group type: EXPERIMENTAL
Intervention: Sintilimab 200 mg plus DEB-TACE
Number of subjects: 60
Study: 36757536

Group type: EXPERIMENTAL
Intervention: Firibastat 100 mg
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Firibastat 500 mg
Number of subjects: 294

Group type: COMPARATOR
Intervention: Ramipril 5 mg
Number of subjects: 294
Study: 36757568

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pazopanib
Number of subjects: 0
Study: 36757611

Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus (64% of cultures)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Methicillin-resistant Staphylococcus aureus (42%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Methicillin-sensitive Staphylococcus aureus (22%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aerobic gram-negative infections (35%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anaerobes (31%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fungi (6%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multi-resistant bacteria (17%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pure aerobic gram-positive cultures (50%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of aerobic gram-positive/gram-negative (8%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pure gram-negative cultures (6%)
Number of subjects: 100
Study: 36757689

Group type: EXPERIMENTAL
Intervention: Cotoretigene toliparvovec (BIIB112/AAV8-RPGR) gene therapy, administered as a single subretinal injection after vitrectomy surgery, with the 4 highest doses administered to 12 participants.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Cotoretigene toliparvovec (BIIB112/AAV8-RPGR) gene therapy (4 highest doses).
Number of subjects: 121

Group type: COMPARATOR
Intervention: Untreated fellow eyes from the XIRIUS study and untreated subgroup from the XOLARIS study.
Number of subjects: 121
Study: 36757690

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid rectal spacer
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control (no spacer)
Number of subjects: 201